ScholarLens Back to search
2014•Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)Requires access

Comparison of fingolimod versus interferon-beta/glatiramer acetate as second-line therapy in active multiple sclerosis

Anna Hanxi He, Tim D. Spelman, Vilija G. Jokubaitis, Alessandra Lugaresi, G. Izquiero, María Trojano, Pierre Grammond, Jan L. Scott, Pierre Duquette, Marc Girard, Eugenio Pucci, Mark Slee, François Grand’Maison, C. Oreja Guevara, Cavit Boz, Ricardo Fernandez Bolanos, Suzanne J Hodgkinson, J. Sanchez Menoyo, Gerardo Iuliano, Michael Harry Barnett, Fraser G. A. Moore, Helmut Butzkueven, Tomáš Kalinčík

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Fingolimod, Glatiramer acetate, Multiple sclerosis, Medicine, Interferon beta-1b, Interferon beta, Interferon beta-1a, Second-line therapy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Comparison of fingolimod versus interferon-beta/glatiramer acetate as second-line therapy in active multiple sclerosis — Research Paper | ScholarLens